Rare diseases
Investigational molecules
Locations
Kuno-Fischer-Strasse 8, Charlottenburg, 14057 Berlin, Germany
The organisation demonstrates substantial engagement in advancing treatment strategies for digestive system malignancies. Research initiatives encompass comprehensive investigations into colorectal cancer, including both metastatic colorectal carcinoma and localised disease presentations. The sponsor supports studies examining peritoneal metastases and their surgical management through cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. Additional focus areas include gastric cancer and gastroesophageal junction tumours, with particular attention to locally advanced disease stages.
Research programmes explore the integration of perioperative chemotherapy regimens and assess the role of neoadjuvant therapy in improving surgical outcomes and patient survival rates.
AIO-Studien gGmbH runs clinical trials in conditions such as Non-small cell lung cancer, Lung neoplasm malignant, Adenocarcinoma of colon, Colon cancer stage III, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on Atezolizumab with FOLFOX for Stage III Colon Cancer with Deficient DNA Mismatch Repair
GermanyTislelizumab with drug combination in patients with PD-L1‑high metastatic non‑small cell lung cancer and high tumor burden
GermanyBMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI
GermanyTesting Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition
GermanyStudy of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer
GermanyStudy on Methadone Hydrochloride and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer
GermanyStudy on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy
GermanyStudy on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
